Publication number:

0 526 700 A3

(9)

EUROPEAN PATENT APPLICATION

2) Application number: 92108527.0

(1) Int. Cl.5: A61K 47/48, A61K 9/127

2 Date of filing: 20.05.92

Priority: 23.05.91 JP 118762/91

② Date of publication of application: 10.02.93 Bulletin 93/06

Designated Contracting States:
 AT BE CH DE DK ES FR GB GR IT LI LU MC
 NL PT SE

Date of deferred publication of the search report:
 26.01.94 Bulletin 94/04

Applicant: MITSUBISHI KASEI CORPORATION
 5-2, Marunouchi 2-chome
 Chiyoda-ku
 Tokyo 100(JP)

Inventor: Tagawa, Toshiaki 3-A102, Sakuradai, Midori-ku Yokohama-shi, Kanagawa-ken(JP) Inventor: Hosokawa, Saiko 1458-25, Okagami; Aso-ku Kawasaki-shi, Kanagawa-ken(JP) Inventor: Nagaike, Kazuhiro 5-7, Sakae-cho

Representative: Wächtershäuser, Günter, Dr.

Sagamihara-shi, Kanagawa-ken(JP)

Tal 29 D-80331 München (DE)

Drug-containing protein-bonded liposome.

A drug-containing protein-bonded liposome comprising a liposome containing a drug and having maleimlde residues on its surface, and a protein and residues of a compound having a polyalkylene glycol moiety, bonded via respective thiol groups to the maleimlde residues.

EP 0 526 700 A3



PARTIAL EUROPEAN SEARCH REPORT

asilenties Number

which under Rule 45 of the European Patent Convention EP 92 10 8527 shall be considered, for the purposes of subsequent proceedings, as the European search report

	DOCUMENTS CONS	IDERED TO BE RELEVAN	T]
Category		Indication, where appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (BLCLS)
E	December 1992 * page 4, line 20	TSUBISHI KASEI CO.) 30 - line 45; figure 5 * - line 51; claim 19 *	1-7	A61K47/48 A61K9/127
Y , X	INC) 26 July 1990 * page 4, line 3 - * page 5, line 16	RO-VESICULAR SYSTEMS, line 30 * line 32 * line 32 * line 18; claims 1,8 *	1-7	
P, A	EP-A-0 448 126 (CAI TECHNOLOGY) 25 Sept * page 7, line 58 - * page 16, line 31 1,2,11 *	- line 5 *	1-7	
	May 1991	DSOME TECHNOLOGY INC.) 2 oh B; claims 1,2,4-6,8 *	1-7	•
		-/	:	TECHNICAL FIELDS SEARCHED (ISLC.5)
1		-7,		A61K
				·
NCO	MPLETE SEARCH			•
be provisi ot a seas Jaims se Jaims se Jaims so Jaims so	h Division considers that the present into of the European Patent Coovent magnet search into the state of the a arched incompletely: arched incompletely: a searched: a the limitation of the search:	Disripmen putent application does not compty isse to such an emtent that it is not possible to ri on the hasis of some of the claims	with carry	
see	sheet C		•	
	THE MACHE	Date of completion of the courts 22. November 1992	000	TC M
THE HAGUE CATEGORY OF CITED DOCUMENTS X: perticularly selevant if taken alone Y: perticularly relevant if considered with another electament of the same category A: exchanged a background				
U : 800	nelegical bechgresse -witten disclosure rmelizie document	me putunt family	, corresponding	



Application Namedow EP 92 10 8527

	DOCUMENTS CONSIDERED TO BE RELEVAN	CLASSIFICATION OF THE APPLICATION (INLCLS)	
Category	Citation of document with indication, where appropriate, of relevant passages	. Relevant to chairs	
Y	JOURNAL OF BIOLOGICAL CHEMISTRY vol. 257, no. 1 , 10 January 1982 , BALTIMORE, MD US pages 286 - 288 F. J. MARTIN 'IRREVERSIBLE COUPLING OG IMMUNOGLOBULIN FRAGMENTS TO PREFORMED VESICLES.' *see abstract*	1-7	
Ρ,Υ	CHEMICAL ABSTRACTS, vol. 115, no. 10, 9 September 1991, Columbus, Ohio, US; abstract no. 99068f, * abstract * & BIOCHIM. BIOPHYS. ACTA vol. 1062, no. 2 , 1991 pages 142 - 148 A. L. KLIBANOV 'ACTIVITY OF AMPHIPATIC POLY(ETHYLENE GLYCOL) 5000 TO PROLONG THE CIRCULATION TIME OF LIPOSOMES DEPENDS ON THE LIPOSOME SIZE AND IS UNFAVORABLE FOR	1-7	TECHNICAL PIELDS SEARCHED (Ind.CL.5)
Y	IMMUNOLIPOSOME BINDING TO TARGET.' WO-A-83 02069 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (BERKELEY)) 23 June 1983 * page 1, line 3 - line 12 * * page 20, line 10 - line 30 * * page 27, line 9 - line 20 * * page 29; line 1 - line 8; claims *	1-7	



INCOMPLETE SEARCH

Claims searched completely : 2,7 Claims searched incompletely : 1,3-6

In view of the large number of compounds, which are defined by the term "proteinbonded liposome of claim 1, the search had to be restricted for economic reasons.

The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see guidelines, Part B, Chapter III, paragraph 3.6).